Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk

Carvalho, Solange Torchia; Stiepcich, Monica Maria; Fregnani, José Humberto; Nonogaki, Sueli; Soares, Fernando Augusto

doi:10.1590/s1807-59322011000400014

Cited by 12 publications

(10 citation statements)

References 32 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this retrospective review, we analyzed the post-radiotherapy pattern of failure and clinical outcome in a cohort of 1,088 patients. As expected, the most prevalent molecular subtype was LA, which is comparable to the Korean and Brazilian cohorts previously reported [8, 10]. Of the four subtypes, the LA subtype tends to have the best prognosis, fairly high survival, and low recurrent or metastases rates.…”

Section: Discussionsupporting

confidence: 86%

Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype

Wu¹,

Baig²,

Kasymjanova³

et al. 2016

Cureus

View full text Add to dashboard Cite

Background and Purpose: No longer considered a single disease entity, breast cancer is being classified into several distinct molecular subtypes based on gene expression profiling. These subtypes appear to carry prognostic implications and have the potential to be incorporated into treatment decisions. In this study, we evaluated patterns of local recurrence (LR), distant metastasis (DM), and association of survival with molecular subtype in breast cancer patients in the post–adjuvant radiotherapy setting.Material and Methods: The medical records of 1,088 consecutive, non-metastatic breast cancer patients treated at a single institution between 2004 and 2012 were reviewed. Estrogen/progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2) enrichment were evaluated by immunohistochemistry. Patients were categorized into one of four subtypes: luminal-A (LA; ER/PR+, HER2-, Grade 1-2), luminal-B (LB; ER/PR+, HER2-, Grade > 2), HER2 over-expression (HER2; ER/PR-, HER2+), and triple negative (TN; ER/PR-, HER2-). Results: The median follow-up time was 6.9 years. During the follow-up, 16% (174/1,088) of patients failed initial treatment and developed either LR (48) or DM (126). The prevalence of LR was the highest in TN (12%) and the lowest in LA (2%). Breast or chest wall relapse was the most frequent site (≈80%) of recurrence in LA, LB, and HER2 subtypes, whereas the regional lymph nodes and chest wall were the common sites of relapse in the TN group (50.0%). DM rates were 6.4% in LA, 12.1% in LB, 19.2% in HER2, and 27.4% in TN subgroups. Five-year survival rates were 84%, 83%, 84%, and 77% in the LA, LB, HER2 and TN subgroups, respectively. There was a statistically significant association between survival and molecular subtypes in an univariate analysis. In the adjusted multivariate analysis, the following variables were independent prognostic factors for survival: T stage, N stage, and molecular subtype.Conclusions: Of the four subtypes, the LA subtype tends to have the best prognosis, fairly high survival, and low recurrent or metastases rates. The TN and HER2 subtypes of breast cancer were associated with significantly poorer overall survival and prone to earlier recurrence and metastases. Our results demonstrate a significant association between molecular subtype and survival. The risk of death and relapse/metastases increases fewfold in TN compared to LA. Future prospective studies are warranted and could ultimately lead to the tailoring of adjuvant radiotherapy treatment fields based on both molecular subtype and the more conventional clinicopathologic characteristics.

show abstract

Section: Discussionsupporting

confidence: 86%

Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype

Wu¹,

Baig²,

Kasymjanova³

et al. 2016

Cureus

View full text Add to dashboard Cite

show abstract

“…Although early stage breast cancer is associated with improved survival, 20% patients still die within 5 years because of disease. The high mortality risk noted in this subset is interrelated with triple negativity (ER, PR and HER2/neunegativity) [7].…”

Section: Introductionmentioning

confidence: 90%

Association of Menopausal Status with Pathological Features of Tumor in Stage I to III A Breast Cancer Patients Treated With Upfront Modified Radical Mastectomy

Mahmood¹

2016

JCPCR

View full text Add to dashboard Cite

Introduction: Breast cancer is the commonest malignancy diagnosed among women worldwide. In Pakistan around 90,000 women are diagnosed with breast cancer every year. Lymphnode involvement, tumor size, receptor status, tumor grade, presence of LVI, age and ethnicity are well recognized prognostic factors for breast cancer. The aim of this study was to evaluate the relationship of menopausal status with pathological and prognostic features of tumor in patients with stage I to III A breast cancer treated upfront with modified radical mastectomy. Material and Methods:This was a single institute observational retrospective study conducted at Nuclear Medicine Oncology and Radiotherapy Institute (NORI) Islamabad. A total of 381 patients with histopathologically proven diagnosis of Invasive ductal carcinoma after modified radical mastectomy were included from January 2009 to December 2013. Age, menopausal status, tumor site, tumor size, grade, lymphnode involvement, receptor status and presence of LVI were recorded on a particularly composed proforma. Statistical analysis for determining the association between menopausal status and pathologic features of tumor was performed using Chi-square test. P value < 0.05 was considered significant. Results:The minimum age of study population was 24 years and maximum age was 80 years with a mean age +/-SD of 48.5 +/-11.1 years. There was a statistically significant association between menopausal status and grade of tumor, lymphovascular invasion and HER2/neuoverexpression (p < 0.05). Conclusion:Grade of tumor, lymphovascular invasion and HER2/neu over expression in stage I to IIIA breast cancer has statistically significant association with menopausal status.

show abstract

“…Tissue microarrays including 62 normal representative paraffin embedded tissue samples from 62 patients with breast cancer were created using a previously reported protocol [27] by the Shanghai Biochip Center. The paraffin embedded tissue samples were obtained from the First Affiliated Hospital of Nanjing Medical University in Nanjing.…”

Section: Methodsmentioning

confidence: 99%

Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo

Yan

Huang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

The oncogene, mouse double minute 2 (MDM2), has been implicated in the pathogenesis of numerous cancers. In this study, we investigated the role of MDM2 in epithelial-to-mesenchymal transition (EMT) and the underlying mechanisms in breast cancer cells in vitro and in vivo. The results showed that up-regulation of MDM2 in MCF-7 cells altered the cell morphology to a mesenchymal phenotype. Knockdown of MDM2 in MDA-MB-231 cells altered the cell morphology to the epithelial phenotype. In addition, overexpression of MDM2 increased the expression of N-cadherin and Vimentin and decreased the expression of E-cadherin, at both the mRNA and protein levels, in vitro and in vivo. Conversely, down-regulation of MDM2 decreased the expression of N-cadherin and Vimentin, and increased the expression of E-cadherin in vitro. Furthermore, MDM2 up-regulated both the mRNA and protein expression of Snail in vitro and in vivo. Knockdown of Snail almost abolished MDM2 induced EMT in vitro. Finally, we found that MDM2 expression correlated with EMT markers and Snail: Snail expression was inversely associated with E-cadherin in human breast cancer samples. Our findings demonstrated that MDM2 induces EMT by enhancing Snail expression in vitro and in vivo. Thus, MDM2 may be a potential target for therapy against human metastatic breast cancer.

show abstract

Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk

Cited by 12 publications

References 32 publications

Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype

Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype

Association of Menopausal Status with Pathological Features of Tumor in Stage I to III A Breast Cancer Patients Treated With Upfront Modified Radical Mastectomy

Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo

Contact Info

Product

Resources

About